5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
<p>Abstract</p> <p>With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer th...
Main Authors: | Hamilton Robert J, Freedland Stephen J |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | BMC Medicine |
Online Access: | http://www.biomedcentral.com/1741-7015/9/105 |
Similar Items
-
Prevention of Prostate Cancer: What We Know and Where We Are Going
by: Jayakrishnan Jayachandran MD, et al.
Published: (2008-06-01) -
Stroke Prevention in Atrial Fibrillation: Where are We Now?
by: Yousif Ahmad, et al.
Published: (2012-01-01) -
Stroke Prevention in Atrial Fibrillation: Where are We Now?
by: Yousif Ahmad, et al.
Published: (2012-02-01) -
Stroke prevention in atrial fibrillation: Where are we now?
by: Gregory Y.H. Lip, MD, FRCP, FESC, FACC
Published: (2015-12-01) -
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)